[{"orgOrder":0,"company":"Meitheal Pharmaceuticals","sponsor":"Premier","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Undisclosed","graph3":"Meitheal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meitheal Pharmaceuticals \/ Premier","highestDevelopmentStatusID":"1","companyTruncated":"Meitheal Pharmaceuticals \/ Premier"},{"orgOrder":0,"company":"Laboratori Derivati Organici","sponsor":"Cerus Dmcc","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"ITALY","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Undisclosed","graph3":"Laboratori Derivati Organici","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratori Derivati Organici \/ Cerus Dmcc","highestDevelopmentStatusID":"1","companyTruncated":"Laboratori Derivati Organici \/ Cerus Dmcc"},{"orgOrder":0,"company":"First Affiliated Hospital of Zhejiang University","sponsor":"Zhejiang University | Ningbo No.2 Hospital | Taizhou Hospital of Zhejiang Province | The Central Hospital of Lishui City | Taizhou Enze Hospital | Taizhou First People's Hospital | Boston Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Undisclosed","graph3":"First Affiliated Hospital of Zhejiang University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"First Affiliated Hospital of Zhejiang University \/ Zhejiang University | Ningbo No.2 Hospital | Taizhou Hospital of Zhejiang Province | The Central Hospital of Lishui City | Taizhou Enze Hospital | Taizhou First People's Hospital | Boston Scientific","highestDevelopmentStatusID":"1","companyTruncated":"First Affiliated Hospital of Zhejiang University \/ Zhejiang University | Ningbo No.2 Hospital | Taizhou Hospital of Zhejiang Province | The Central Hospital of Lishui City | Taizhou Enze Hospital | Taizhou First People's Hospital | Boston Scientific"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Anthos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Partnership","leadProduct":"Abelacimab","moa":"Coagulation factor XI","graph1":"Hematology","graph2":"Undisclosed","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Biologics Inc \/ Anthos Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Lonza Biologics Inc \/ Anthos Therapeutics"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Bionical Emas","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Hematology","graph2":"Undisclosed","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"G1 Therapeutics, Inc \/ Bionical Emas","highestDevelopmentStatusID":"1","companyTruncated":"G1 Therapeutics, Inc \/ Bionical Emas"},{"orgOrder":0,"company":"VarmX","sponsor":"Ysios Capital","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"NETHERLANDS","productType":"Enzyme","year":"2020","type":"Series B Financing","leadProduct":"VMX-C001","moa":"Factor Xa","graph1":"Hematology","graph2":"Undisclosed","graph3":"VarmX","amount2":0.040000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"VarmX \/ Ysios Capital","highestDevelopmentStatusID":"1","companyTruncated":"VarmX \/ Ysios Capital"},{"orgOrder":0,"company":"King Hussein Cancer Center","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JORDAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Undisclosed","graph3":"King Hussein Cancer Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"King Hussein Cancer Center \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"King Hussein Cancer Center \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"IBSA Institut Biochimique","sponsor":"Informapro Srl","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"Ferritin light chain; Hemoglobin subunit alpha; Hemoglobin subunit beta","graph1":"Hematology","graph2":"Undisclosed","graph3":"IBSA Institut Biochimique","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IBSA Institut Biochimique \/ Informapro Srl","highestDevelopmentStatusID":"1","companyTruncated":"IBSA Institut Biochimique \/ Informapro Srl"},{"orgOrder":0,"company":"Hangzhou Agile Groups Network Technology Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Iron","moa":"Hemoglobin (HB)","graph1":"Hematology","graph2":"Undisclosed","graph3":"Hangzhou Agile Groups Network Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hangzhou Agile Groups Network Technology Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Hangzhou Agile Groups Network Technology Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"PharmaLinea","sponsor":"Clinres Farmacija","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Iron","moa":"Hemoglobin (HB)","graph1":"Hematology","graph2":"Undisclosed","graph3":"PharmaLinea","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaLinea \/ Clinres Farmacija","highestDevelopmentStatusID":"1","companyTruncated":"PharmaLinea \/ Clinres Farmacija"},{"orgOrder":0,"company":"University of Calgary","sponsor":"Mitacs | Natural Sciences and Engineering Research Council, Canada","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Ferrous Sulfate","moa":"Iron stores","graph1":"Hematology","graph2":"Undisclosed","graph3":"University of Calgary","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Calgary \/ Mitacs | Natural Sciences and Engineering Research Council, Canada","highestDevelopmentStatusID":"1","companyTruncated":"University of Calgary \/ Mitacs | Natural Sciences and Engineering Research Council, Canada"},{"orgOrder":0,"company":"PharmaLinea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ferrous Sulfate","moa":"Iron stores","graph1":"Hematology","graph2":"Undisclosed","graph3":"PharmaLinea","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaLinea \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"PharmaLinea \/ Undisclosed"},{"orgOrder":0,"company":"Fundaci\u00f3 Eurecat","sponsor":"Laboratorio Echevarne | Health Tech Bio Actives, S.L.U.","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SPAIN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Methylcobalamin","moa":"Methionine synthase","graph1":"Hematology","graph2":"Undisclosed","graph3":"Fundaci\u00f3 Eurecat","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fundaci\u00f3 Eurecat \/ Laboratorio Echevarne | Health Tech Bio Actives, S.L.U.","highestDevelopmentStatusID":"1","companyTruncated":"Fundaci\u00f3 Eurecat \/ Laboratorio Echevarne | Health Tech Bio Actives, S.L.U."},{"orgOrder":0,"company":"S.LAB (SOLOWAYS)","sponsor":"Triangel Scientific | Center of New Medical Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"RUSSIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Nicotinamide","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"S.LAB (SOLOWAYS)","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"S.LAB (SOLOWAYS) \/ Triangel Scientific | Center of New Medical Technologies","highestDevelopmentStatusID":"1","companyTruncated":"S.LAB (SOLOWAYS) \/ Triangel Scientific | Center of New Medical Technologies"},{"orgOrder":0,"company":"Cellphire Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Thrombosomes","moa":"Platelet level","graph1":"Hematology","graph2":"Undisclosed","graph3":"Cellphire Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellphire Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Cellphire Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Superficial Siderosis Research Alliance Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Inosine","moa":"Purine nucleoside phosphorylase; IAG-nucleoside hydrolase; Purine nucleoside phosphorylase DeoD-type","graph1":"Hematology","graph2":"Undisclosed","graph3":"Superficial Siderosis Research Alliance Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Superficial Siderosis Research Alliance Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Superficial Siderosis Research Alliance Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Lowell Therapeutics","sponsor":"AcelRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Nafamostat","moa":"enzyme inhibitors: proteolytic enzyme inhibitors","graph1":"Hematology","graph2":"Undisclosed","graph3":"Lowell Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lowell Therapeutics \/ AcelRx Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Lowell Therapeutics \/ AcelRx Pharmaceuticals"},{"orgOrder":0,"company":"Yunfeng Cheng","sponsor":"Shanghai Zhongshan Hospital | Shanghai Jinshan Hospital | Zhongshan Qingpu Hospital, Fudan University | Zhongshan Wusong Hospital, Fudan University | Macau University of Science and Technology Hospital | Health and Humanity Research Centre, Hongkong | Dr.","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Hematology","graph2":"Undisclosed","graph3":"Yunfeng Cheng","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Yunfeng Cheng \/ Shanghai Zhongshan Hospital | Shanghai Jinshan Hospital | Zhongshan Qingpu Hospital, Fudan University | Zhongshan Wusong Hospital, Fudan University | Macau University of Science and Technology Hospital | Health and Humanity Research Centre, Hongkong | Dr.","highestDevelopmentStatusID":"1","companyTruncated":"Yunfeng Cheng \/ Shanghai Zhongshan Hospital | Shanghai Jinshan Hospital | Zhongshan Qingpu Hospital, Fudan University | Zhongshan Wusong Hospital, Fudan University | Macau University of Science and Technology Hospital | Health and Humanity Research Centre, Hongkong | Dr."},{"orgOrder":0,"company":"Yunfeng Cheng","sponsor":"Shanghai Zhongshan Hospital | Shanghai Jinshan Hospital | Zhongshan Qingpu Hospital, Fudan University | Zhongshan Wusong Hospital, Fudan University | Macau University of Science and Technology Hospital | Health and Humanity Research Centre, Hongkong | Dr.","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Hematology","graph2":"Undisclosed","graph3":"Yunfeng Cheng","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Yunfeng Cheng \/ Shanghai Zhongshan Hospital | Shanghai Jinshan Hospital | Zhongshan Qingpu Hospital, Fudan University | Zhongshan Wusong Hospital, Fudan University | Macau University of Science and Technology Hospital | Health and Humanity Research Centre, Hongkong | Dr.","highestDevelopmentStatusID":"1","companyTruncated":"Yunfeng Cheng \/ Shanghai Zhongshan Hospital | Shanghai Jinshan Hospital | Zhongshan Qingpu Hospital, Fudan University | Zhongshan Wusong Hospital, Fudan University | Macau University of Science and Technology Hospital | Health and Humanity Research Centre, Hongkong | Dr."},{"orgOrder":0,"company":"Yunfeng Cheng","sponsor":"Shanghai Zhongshan Hospital | Shanghai Jinshan Hospital | Zhongshan Qingpu Hospital, Fudan University | Zhongshan Wusong Hospital, Fudan University | Macau University of Science and Technology Hospital | Health and Humanity Research Centre, Hongkong | Dr.","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Hematology","graph2":"Undisclosed","graph3":"Yunfeng Cheng","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Yunfeng Cheng \/ Shanghai Zhongshan Hospital | Shanghai Jinshan Hospital | Zhongshan Qingpu Hospital, Fudan University | Zhongshan Wusong Hospital, Fudan University | Macau University of Science and Technology Hospital | Health and Humanity Research Centre, Hongkong | Dr.","highestDevelopmentStatusID":"1","companyTruncated":"Yunfeng Cheng \/ Shanghai Zhongshan Hospital | Shanghai Jinshan Hospital | Zhongshan Qingpu Hospital, Fudan University | Zhongshan Wusong Hospital, Fudan University | Macau University of Science and Technology Hospital | Health and Humanity Research Centre, Hongkong | Dr."},{"orgOrder":0,"company":"Dr. Anil K. Gupta Medicine Professional Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Ferrous Fumarate","moa":"Transferrin receptor protein 1; Egl nine homolog 1; Histone deacetylase 8; Alpha-hemoglobin-stabilizing protein; Hemoglobin subunit alpha; Frataxin, mitochondrial; Ferritin heavy chain; Flap endonuclease 1; Endonuclease 8-like 1; Endonuclease 8-like 2; DNA polymerase beta; Ceruloplasmin; Serotransferrin","graph1":"Hematology","graph2":"Undisclosed","graph3":"Dr. Anil K. Gupta Medicine Professional Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Anil K. Gupta Medicine Professional Corporation \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Dr. Anil K. Gupta Medicine Professional Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Egymedicalpedia","sponsor":"Al-Azhar University","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Lactoferrin","moa":"Tryptase alpha\/beta-1 (Tryptase)","graph1":"Hematology","graph2":"Undisclosed","graph3":"Egymedicalpedia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egymedicalpedia \/ Al-Azhar University","highestDevelopmentStatusID":"1","companyTruncated":"Egymedicalpedia \/ Al-Azhar University"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nilotinib","moa":"Tyrosine-protein kinase ABL","graph1":"Hematology","graph2":"Undisclosed","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai BDgene","sponsor":"923rd Hospital of Joint Logistics Support Force of PLA","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BD211","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"Shanghai BDgene","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai BDgene \/ 923rd Hospital of Joint Logistics Support Force of PLA","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai BDgene \/ 923rd Hospital of Joint Logistics Support Force of PLA"},{"orgOrder":0,"company":"University of Ulster","sponsor":"Solvotrin Therapeutics - Active Iron | National Health Service, UK","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Adipreg","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"University of Ulster","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Ulster \/ Solvotrin Therapeutics - Active Iron | National Health Service, UK","highestDevelopmentStatusID":"1","companyTruncated":"University of Ulster \/ Solvotrin Therapeutics - Active Iron | National Health Service, UK"},{"orgOrder":0,"company":"University of Westminster","sponsor":"Gencor Pacific Group","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ferrous Sulfate","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"University of Westminster","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Westminster \/ Gencor Pacific Group","highestDevelopmentStatusID":"1","companyTruncated":"University of Westminster \/ Gencor Pacific Group"},{"orgOrder":0,"company":"Sidero Bioscience","sponsor":"SRS Life Sciences Pte ltd","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Agreement","leadProduct":"FTH1","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"Sidero Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidero Bioscience \/ SRS Life Sciences Pte ltd","highestDevelopmentStatusID":"1","companyTruncated":"Sidero Bioscience \/ SRS Life Sciences Pte ltd"},{"orgOrder":0,"company":"GATT Technologies BV","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"NETHERLANDS","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GATT-Patch","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"GATT Technologies BV","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Patch","sponsorNew":"GATT Technologies BV \/ Syneos Health","highestDevelopmentStatusID":"1","companyTruncated":"GATT Technologies BV \/ Syneos Health"},{"orgOrder":0,"company":"Shanghai Cell Therapy Group","sponsor":"Baize Plan Fund","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Collaboration","leadProduct":"Hematopoietic Stem Cell","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"Shanghai Cell Therapy Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Cell Therapy Group \/ Baize Plan Fund","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai Cell Therapy Group \/ Baize Plan Fund"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"QATAR","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Human Plasma Protein Fraction","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hamad Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Hamad Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"University of Westminster","sponsor":"Pharmako Biotechnologies Pty Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"HydroCurc","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"University of Westminster","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Westminster \/ Pharmako Biotechnologies Pty Ltd","highestDevelopmentStatusID":"1","companyTruncated":"University of Westminster \/ Pharmako Biotechnologies Pty Ltd"},{"orgOrder":0,"company":"Sourse","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Hype Bites Supplement","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"Sourse","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sourse \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Sourse \/ Citruslabs"},{"orgOrder":0,"company":"IBSA Institut Biochimique","sponsor":"Informapro Srl","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ibsa Iron Odf","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"IBSA Institut Biochimique","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Film, Dispersible","sponsorNew":"IBSA Institut Biochimique \/ Informapro Srl","highestDevelopmentStatusID":"1","companyTruncated":"IBSA Institut Biochimique \/ Informapro Srl"},{"orgOrder":0,"company":"NovoBliss Research","sponsor":"Orgenetics, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Iron Exctract","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"NovoBliss Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NovoBliss Research \/ Orgenetics, Inc.","highestDevelopmentStatusID":"1","companyTruncated":"NovoBliss Research \/ Orgenetics, Inc."},{"orgOrder":0,"company":"Akram Medical Complex","sponsor":"Scotmann Pharmaceuticals | The Searle Company Limited Pakistan","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"PAKISTAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Iron III Hydroxide Polymaltose Complex","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"Akram Medical Complex","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akram Medical Complex \/ Scotmann Pharmaceuticals | The Searle Company Limited Pakistan","highestDevelopmentStatusID":"1","companyTruncated":"Akram Medical Complex \/ Scotmann Pharmaceuticals | The Searle Company Limited Pakistan"},{"orgOrder":0,"company":"Applied Science & Performance Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Iron Supplement","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"Applied Science & Performance Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Science & Performance Institute \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Applied Science & Performance Institute \/ Undisclosed"},{"orgOrder":0,"company":"Hangzhou Agile Groups Network Technology Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Minayo Yeast","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"Hangzhou Agile Groups Network Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hangzhou Agile Groups Network Technology Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Hangzhou Agile Groups Network Technology Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Nogapendekin-Alfa Inbakicept","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmunityBio \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"ImmunityBio \/ Undisclosed"},{"orgOrder":0,"company":"Lindenwood University","sponsor":"Increnovo, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Time To Exhaustion At Velocity At Vo2Max","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"Lindenwood University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lindenwood University \/ Increnovo, LLC","highestDevelopmentStatusID":"1","companyTruncated":"Lindenwood University \/ Increnovo, LLC"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Qualia Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Qualia Iron","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"Qualia Life Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Qualia Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Qualia Life Sciences \/ Undisclosed"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Qualia Life Sciences

                          Country arrow
                          FNCE
                          Not Confirmed

                          Qualia Life Sciences

                          Country arrow
                          FNCE
                          Not Confirmed

                          Details : Qualia Iron is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in Undisclosed clinical studies for the treatment of Iron Deficiencies.

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          September 05, 2025

                          Lead Product(s) : Qualia Iron

                          Therapeutic Area : Hematology

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          University of Westminster

                          Country arrow
                          FNCE
                          Not Confirmed

                          University of Westminster

                          Country arrow
                          FNCE
                          Not Confirmed

                          Details : HydroCurc is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Iron Deficiencies.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          July 22, 2025

                          Lead Product(s) : HydroCurc

                          Therapeutic Area : Hematology

                          Highest Development Status : Undisclosed

                          Sponsor : Pharmako Biotechnologies Pty Ltd

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : Nogapendekin-Alfa Inbakicept is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Lymphopenia.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          May 04, 2025

                          Lead Product(s) : Nogapendekin-Alfa Inbakicept

                          Therapeutic Area : Hematology

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          University of Calgary

                          Country arrow
                          FNCE
                          Not Confirmed

                          University of Calgary

                          Country arrow
                          FNCE
                          Not Confirmed

                          Details : Ferrous Sulfate is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of Iron Deficiencies.

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          April 24, 2025

                          Lead Product(s) : Ferrous Sulfate

                          Therapeutic Area : Hematology

                          Highest Development Status : Undisclosed

                          Sponsor : Mitacs | Natural Sciences and Engineering Research Council, Canada

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : Bezuclastinib is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Mastocytosis, Systemic.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 08, 2025

                          Lead Product(s) : Bezuclastinib

                          Therapeutic Area : Hematology

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Hangzhou Agile Groups Network Technology Co., Ltd.

                          Country arrow
                          FNCE
                          Not Confirmed

                          Hangzhou Agile Groups Network Technology Co., Ltd.

                          Country arrow
                          FNCE
                          Not Confirmed

                          Details : Iron is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of Anemia.

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          March 11, 2025

                          Lead Product(s) : Iron

                          Therapeutic Area : Hematology

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Chia Tai Tianqing Pharmaceutical Group

                          Country arrow
                          FNCE
                          Not Confirmed

                          Chia Tai Tianqing Pharmaceutical Group

                          Country arrow
                          FNCE
                          Not Confirmed

                          Details : This drug candidate is currently being evaluated in clinical studies for the treatment of Thrombocytopenia.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          January 10, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Hematology

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Chia Tai Tianqing Pharmaceutical Group

                          Country arrow
                          FNCE
                          Not Confirmed

                          Chia Tai Tianqing Pharmaceutical Group

                          Country arrow
                          FNCE
                          Not Confirmed

                          Details : This drug candidate is currently being evaluated in clinical studies for the treatment of Thrombocytopenia.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          January 10, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Hematology

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Egymedicalpedia

                          Country arrow
                          FNCE
                          Not Confirmed

                          Egymedicalpedia

                          Country arrow
                          FNCE
                          Not Confirmed

                          Details : Lactoferrin is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of Anemia, Iron-Deficiency.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          September 19, 2024

                          Lead Product(s) : Lactoferrin

                          Therapeutic Area : Hematology

                          Highest Development Status : Undisclosed

                          Sponsor : Al-Azhar University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Yunfeng Cheng

                          Country arrow
                          FNCE
                          Not Confirmed

                          Yunfeng Cheng

                          Country arrow
                          FNCE
                          Not Confirmed

                          Lead Product(s) : Hydroxychloroquine Sulphate

                          Therapeutic Area : Hematology

                          Study Phase : Undisclosed

                          Sponsor : Shanghai Zhongshan Hospital | Shanghai Jinshan Hospital | Zhongshan Qingpu Hospital, Fudan University | Zhongshan Wusong Hospital, Fudan University | Macau University of Science and Technology Hospital | Health and Humanity Research Centre, Hongkong | Dr.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Hydroxychloroquine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Thrombocytopenia.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 28, 2024

                          Lead Product(s) : Hydroxychloroquine Sulphate

                          Therapeutic Area : Hematology

                          Highest Development Status : Undisclosed

                          Sponsor : Shanghai Zhongshan Hospital | Shanghai Jinshan Hospital | Zhongshan Qingpu Hospital, Fudan University | Zhongshan Wusong Hospital, Fudan University | Macau University of Science and Technology Hospital | Health and Humanity Research Centre, Hongkong | Dr.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank